The observed trend is likely to be driven by advancements in technologies in pneumoconiosis diagnostics, including the emergence of validated biomarker (e.g., KL-6, MMP-2) and the continuous evolution of AI-assisted imaging analysis systems for pneumoconiosis (23, 24). This evidence concerns the gene MMP2 and pneumoconiosis.